Levi & Korsinsky, LLP announces that a VERU class action lawsuit has been filed on behalf of investors who purchased Veru Inc. (VERU) securities between May 11, 2022, and November 9, 2022 For more on the VERU Lawsuit please contact us today.

According to the Veru lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: 1) the Company had withheld material adverse facts about the data from the sabizabulin Phase 3 trial and the Company’s interactions with the United States Food and Drug Administration; 2) defendants misled Veru’s shareholders to believe that the data from the sabizabulin Phase 3 trial was sufficient to support Emergency Use Authorization (“EUA”) and even the submission of a New Drug Application without any further studies; and 3) the Company’s filings concealed the true risks faced by Veru in gaining approval for its EUA request.

TO LEARN MORE ABOUT THE VERU CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Veru you have until February 6, 2023, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com